NISAN - the National Institute for Stroke and Applied Neurosciences
Permanent link for this collection
Institute Director: Professor Valery Feigin
Deputy Director: Associate Professor Alice Theadom
The National Institute for Stroke and Applied Neurosciences (NISAN) conducts epidemiological studies and clinical trials to improve health and outcomes in people with major neurological disorders. Current research programmes focus on:
- Stroke
- Traumatic brain injury
- Neuromuscular disorders
- Neuroepidemiology
- Public health
- Neurorehabilitation
- Neuropsychology
- Biostatistics
Browse
Browsing NISAN - the National Institute for Stroke and Applied Neurosciences by Author "Abajobir, AA"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemGlobal, Regional, and Country-specific Lifetime Risks of Stroke, 1990 and 2016(Massachusetts Medical Society, 2018) GBD 2016 Lifetime Risk of Stroke Collaborators; Feigin, VL; Nguyen, G; Cercy, K; Johnson, CO; Alam, T; Parmar, PG; Abajobir, AA; Abate, KH; Abd-Allah, F; Abejie, AN; Abyu, GY; Ademi, Z; Agarwal, G; Ahmed, MB; Akinyemi, RO; Al-Raddadi, R; Aminde, LN; Amlie-Lefond, C; Ansari, H; Asayesh, H; Asgedom, SW; Atey, TM; Ayele, HT; Banach, M; Banerjee, A; Barac, A; Barker-Collo, SL; Bärnighausen, T; Barregard, L; Basu, S; Bedi, N; Behzadifar, M; Béjot, Y; Bennett, DA; Bensenor, IM; Berhe, DF; Boneya, DJ; Brainin, M; Campos-Nonato, IR; Caso, V; Castañeda-Orjuela, CA; Rivas, JC; Catalá-López, F; Christensen, H; Criqui, MH; Damasceno, A; Dandona, L; Dandona, R; Davletov, K; de Courten, B; deVeber, G; Dokova, K; Edessa, D; Endres, M; Faraon, EJA; Farvid, MS; Fischer, F; Foreman, K; Forouzanfar, MH; Gall, SL; Gebrehiwot, TT; Geleijnse, JM; Gillum, RF; Giroud, M; Goulart, AC; Gupta, R; Gupta, R; Hachinski, V; Hamadeh, RR; Hankey, GJ; Hareri, HA; Havmoeller, R; Hay, SI; Hegazy, MI; Hibstu, DT; James, SL; Jeemon, P; John, D; Jonas, JB; Jóźwiak, J; Kalani, R; Kandel, A; Kasaeian, A; Kengne, AP; Khader, YS; Khan, AR; Khang, Y-H; Khubchandani, J; Kim, D; Kim, YJ; Kivimaki, M; Kokubo, Y; Kolte, D; Kopec, JA; Kosen, S; Kravchenko, M; Krishnamurthi, R; Kumar, GA; Lafranconi, A; Lavados, PM; Legesse, Y; Li, Y; Liang, X; Lo, WD; Lorkowski, S; Lotufo, PA; Loy, CT; Mackay, MT; Abd El Razek, HM; Mahdavi, M; Majeed, A; Malekzadeh, R; Malta, DC; Mamun, AA; Mantovani, LG; Martins, SCO; Mate, KK; Mazidi, M; Mehata, S; Meier, T; Melaku, YA; Mendoza, W; Mensah, GA; Meretoja, A; Mezgebe, HB; Miazgowski, T; Miller, TR; Ibrahim, NM; Mohammed, S; Mokdad, AH; Moosazadeh, M; Moran, AE; Musa, KI; Negoi, RI; Nguyen, M; Nguyen, QL; Nguyen, TH; Tran, TT; Nguyen, TT; Anggraini Ningrum, DN; Norrving, B; Noubiap, JJ; O’Donnell, MJ; Olagunju, AT; Onuma, OK; Owolabi, MO; Parsaeian, M; Patton, GC; Piradov, M; Pletcher, MA; Pourmalek, F; Prakash, V; Qorbani, M; Rahman, M; Rahman, MA; Rai, RK; Ranta, A; Rawaf, D; Rawaf, S; Renzaho, AMN; Robinson, SR; Sahathevan, R; Sahebkar, A; Salomon, JA; Santalucia, P; Santos, IS; Sartorius, B; Schutte, AE; Sepanlou, SG; Shafieesabet, A; Shaikh, MA; Shamsizadeh, M; Sheth, KN; Sisay, M; Shin, M-J; Shiue, I; Silva, DAS; Sobngwi, E; Soljak, M; Sorensen, RJD; Sposato, LA; Stranges, S; Suliankatchi, RA; Tabarés-Seisdedos, R; Tanne, D; Nguyen, CT; Thakur, JS; Thrift, AG; Tirschwell, DL; Topor-Madry, R; Tran, BX; Nguyen, LT; Truelsen, T; Tsilimparis, N; Tyrovolas, S; Ukwaja, KN; Uthman, OA; Varakin, Y; Vasankari, T; Venketasubramanian, N; Vlassov, VV; Wang, W; Werdecker, A; Wolfe, CDA; Xu, G; Yano, Y; Yonemoto, N; Yu, C; Zaidi, Z; El Sayed Zaki, M; Zhou, M; Ziaeian, B; Zipkin, B; Vos, T; Naghavi, M; Murray, CJL; Roth, GABACKGROUND: The lifetime risk of stroke has been calculated in a limited number of selected populations. We sought to estimate the lifetime risk of stroke at the regional, country, and global level using data from a comprehensive study of the prevalence of major diseases. METHODS: We used the Global Burden of Disease (GBD) Study 2016 estimates of stroke incidence and the competing risks of death from any cause other than stroke to calculate the cumulative lifetime risks of first stroke, ischemic stroke, or hemorrhagic stroke among adults 25 years of age or older. Estimates of the lifetime risks in the years 1990 and 2016 were compared. Countries were categorized into quintiles of the sociodemographic index (SDI) used in the GBD Study, and the risks were compared across quintiles. Comparisons were made with the use of point estimates and uncertainty intervals representing the 2.5th and 97.5th percentiles around the estimate. RESULTS: The estimated global lifetime risk of stroke from the age of 25 years onward was 24.9% (95% uncertainty interval, 23.5 to 26.2); the risk among men was 24.7% (95% uncertainty interval, 23.3 to 26.0), and the risk among women was 25.1% (95% uncertainty interval, 23.7 to 26.5). The risk of ischemic stroke was 18.3%, and the risk of hemorrhagic stroke was 8.2%. In high-SDI, high-middle-SDI, and low-SDI countries, the estimated lifetime risk of stroke was 23.5%, 31.1% (highest risk), and 13.2% (lowest risk), respectively; the 95% uncertainty intervals did not overlap between these categories. The highest estimated lifetime risks of stroke according to GBD region were in East Asia (38.8%), Central Europe (31.7%), and Eastern Europe (31.6%), and the lowest risk was in eastern sub-Saharan Africa (11.8%). The mean global lifetime risk of stroke increased from 22.8% in 1990 to 24.9% in 2016, a relative increase of 8.9% (95% uncertainty interval, 6.2 to 11.5); the competing risk of death from any cause other than stroke was considered in this calculation. CONCLUSIONS: In 2016, the global lifetime risk of stroke from the age of 25 years onward was approximately 25% among both men and women. There was geographic variation in the lifetime risk of stroke, with the highest risks in East Asia, Central Europe, and Eastern Europe. (Funded by the Bill and Melinda Gates Foundation.).
- ItemGlobal, Regional, and National Burden of Neurological Disorders During 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015(Elsevier, 2017) Feigin, VL; Abajobir, AA; Abate, KH; Abd-Allah, F; Abdulle, AM; Abera, SF; Abyu, GY; Ahmed, MB; Aichour, AN; Aichour, I; Aichour, MTE; Akinyemi, RO; Alabed, S; Al-Raddadi, R; Alvis-Guzman, N; Amare, AT; Ansari, H; Anwari, P; Arnlov, J; Asayesh, H; Asgedom, SW; Atey, TM; Avila-Burgos, L; Avokpaho, EFGA; Azarpazhooh, MR; Barac, A; Barboza, M; Barker-Collo, SL; Baernighausen, T; Bedi, N; Beghi, E; Bennett, DA; Bensenor, IM; Berhane, A; Betsu, BD; Bhaumik, S; Birlik, SM; Biryukov, S; Boneya, DJ; Bulto, LN; Carabin, H; Casey, D; Castaneda-Orjuela, CA; Catala-Lopez, F; Chen, H; Chitheer, AA; Chowdhury, R; Christensen, H; Dandona, L; Dandona, R; deVeber, GA; Dharmaratne, SD; Do, HP; Dokova, K; Dorsey, ER; Ellenbogen, RG; Eskandarieh, S; Farvid, MS; Fereshtehnejad, S-M; Fischer, F; Foreman, KJ; Geleijnse, JM; Gillum, RF; Giussani, G; Goldberg, EM; Gona, PN; Goulart, AC; Gugnani, HC; Gupta, R; Gupta, R; Hachinski, V; Hamadeh, RR; Hambisa, M; Hankey, GJ; Hareri, HA; Havmoeller, R; Hay, SI; Heydarpour, P; Hotez, PJ; Jakovljevic, MMB; Javanbakht, M; Jeemon, P; Jonas, JB; Kalkonde, Y; Kandel, A; Karch, A; Kasaeian, A; Kastor, A; Keiyoro, PN; Khader, YS; Khalil, IA; Khan, EA; Khang, Y-H; Khoja, AT; Khubchandani, J; Kulkarni, C; Kim, D; Kim, YJ; Kivimaki, M; Kokubo, Y; Kosen, S; Kravchenko, M; Krishnamurthi, RV; Defo, BK; Kumar, GA; Kumar, R; Kyu, HH; Larsson, A; Lavados, PM; Li, Y; Liang, X; Liben, ML; Lo, WD; Logroscino, G; Lotufo, PA; Loy, CT; Mackay, MT; Abd El Razek, HM; Abd El Razek, MM; Majeed, A; Malekzadeh, R; Manhertz, T; Mantovani, LG; Massano, J; Mazidi, M; McAlinden, C; Mehata, S; Mehndiratta, MM; Memish, ZA; Mendoza, W; Mengistie, MA; Mensah, GA; Meretoja, A; Mezgebe, HB; Miller, TR; Mishra, SR; Ibrahim, NM; Mohammadi, A; Mohammed, KE; Mohammed, S; Mokdad, AH; Moradi-Lakeh, M; Velasquez, IM; Musa, KI; Naghavi, M; Ngunjiri, JW; Nguyen, CT; Nguyen, G; Nguyen, QL; Nguyen, TH; Nichols, E; Ningrum, DN; Nong, VM; Norrving, B; Noubiap, JJN; Ogbo, FA; Owolabi, MO; Pandian, JD; Parmar, PG; Pereira, DM; Petzold, M; Phillips, MR; Piradov, MA; Poulton, RG; Pourmalek, F; Qorbani, M; Rafay, A; Rahman, M; Rahman, MH; Rai, RK; Rajsic, S; Ranta, A; Rawaf, S; Renzaho, AMN; Rezai, MS; Roth, GA; Roshandel, G; Rubagotti, E; Sachdev, P; Safiri, S; Sahathevan, R; Sahraian, MA; Samy, AM; Santalucia, P; Santos, IS; Sartorius, B; Satpathy, M; Sawhney, M; Saylan, MI; Sepanlou, SG; Shaikh, MA; Shakir, R; Shamsizadeh, M; Sheth, KN; Shigematsu, M; Shoman, H; Silva, DA; Smith, M; Sobngwi, E; Sposato, LA; Stanaway, JD; Stein, DJ; Steiner, TJ; Stovner, LJ; Abdulkader, RS; Szoeke, CEI; Tabares-Seisdedos, R; Tanne, D; Theadom, AM; Thrift, AG; Tirschwell, DL; Topor-Madry, R; Tran, BX; Truelsen, T; Tuem, KB; Ukwaja, KN; Uthman, OA; Varakin, YY; Vasankari, T; Venketasubramanian, N; Vlassov, VV; Wadilo, F; Wakayo, T; Wallin, MT; Weiderpass, E; Westerman, R; Wijeratne, T; Wiysonge, CS; Woldu, MA; Wolfe, CDA; Xavier, D; Xu, G; Yano, Y; Yimam, HH; Yonemoto, N; Yu, C; Zaidi, Z; Zaki, MES; Zunt, JR; Murray, CJL; Vos, T; Disorders, GBDNBackground Comparable data on the global and country-specific burden of neurological disorders and their trends are crucial for health-care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study provides such information but does not routinely aggregate results that are of interest to clinicians specialising in neurological conditions. In this systematic analysis, we quantified the global disease burden due to neurological disorders in 2015 and its relationship with country development level. Methods We estimated global and country-specific prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) for various neurological disorders that in the GBD classification have been previously spread across multiple disease groupings. The more inclusive grouping of neurological disorders included stroke, meningitis, encephalitis, tetanus, Alzheimer's disease and other dementias, Parkinson's disease, epilepsy, multiple sclerosis, motor neuron disease, migraine, tension-type headache, medication overuse headache, brain and nervous system cancers, and a residual category of other neurological disorders. We also analysed results based on the Socio-demographic Index (SDI), a compound measure of income per capita, education, and fertility, to identify patterns associated with development and how countries fare against expected outcomes relative to their level of development. Findings Neurological disorders ranked as the leading cause group of DALYs in 2015 (250·7 [95% uncertainty interval (UI) 229·1 to 274·7] million, comprising 10·2% of global DALYs) and the second-leading cause group of deaths (9·4 [9·1 to 9·7] million], comprising 16·8% of global deaths). The most prevalent neurological disorders were tension-type headache (1505·9 [UI 1337·3 to 1681·6 million cases]), migraine (958·8 [872·1 to 1055·6] million), medication overuse headache (58·5 [50·8 to 67·4 million]), and Alzheimer's disease and other dementias (46·0 [40·2 to 52·7 million]). Between 1990 and 2015, the number of deaths from neurological disorders increased by 36·7%, and the number of DALYs by 7·4%. These increases occurred despite decreases in age-standardised rates of death and DALYs of 26·1% and 29·7%, respectively; stroke and communicable neurological disorders were responsible for most of these decreases. Communicable neurological disorders were the largest cause of DALYs in countries with low SDI. Stroke rates were highest at middle levels of SDI and lowest at the highest SDI. Most of the changes in DALY rates of neurological disorders with development were driven by changes in YLLs. Interpretation Neurological disorders are an important cause of disability and death worldwide. Globally, the burden of neurological disorders has increased substantially over the past 25 years because of expanding population numbers and ageing, despite substantial decreases in mortality rates from stroke and communicable neurological disorders. The number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades. Policy makers and health-care providers should be aware of these trends to provide adequate services.